News
Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback